Sunitinib, a multitarget tyrosine kinase inhibitor (TKI) that inhibits VEGFR1, R2, R3, platelet-derived growth factor receptors, and stem cell factor receptor, has been shown to suppress PD-1 expression at the mRNA level in tumor-infiltrating T cells [43, 55]. The gene discussed is PDCD1; the disease is neoplasm.